A short video by McCall McPherson discussing subclinical hypothyroidism and clinicians' tendency to delay treatment despite patients' symptoms and reduced quality of life. The speaker notes a trend since ~2018–2019 toward greater stratification and withholding treatment, and references two main studies influencing this shift.
Chapters
The reason this is a big deal right now is because this is a lot of the occurrences where people go in and you get labs drawn and you have all these thyroid symptoms and your clinician says, you know, you've got this mild thing going on, but it's not bad enough to treat. Let's wait, we'll recheck it again next year. And you leave usually pretty disheartened, usually pretty frustrated, because you feel horrible, but no one wants to do anything about it. And not only does that compromise your quality of life, it compromises so much more. For the last several years, I really noticed it Starting in about 2018, 2019, medicine has begun to more and more further stratify people with all these different. In all these different ways, whether it's age, whether it's labs, whether it's continent, whatever it is, and say that we should not treat them, that we should delay treatment. And this really started in the world of subclinical hypothyroidism with two main studies. Ride this out with me, all because it's fascinating and you won't honestly hear this anywhere else.